Autobio Diagnostics (603658) Q3 2026 earnings summary

Executive summary

• Q3 revenue rose 10.76% YoY to RMB 1.182bn; attributable net income increased 21.30% to RMB 350.0m.

• 9M revenue grew 3.59% to RMB 3.240bn, while attributable net income declined 1.45% to RMB 847.1m.

Financial highlights

• Q3 total profit was RMB 387.1m, up 20.85% YoY; adjusted attributable net income was RMB 334.7m, up 24.34%.

• 9M total profit was RMB 933.3m, down 2.70% YoY; adjusted attributable net income was RMB 827.9m, up 1.52%.

• 9M operating profit was RMB 940.1m versus RMB 952.2m; net income was RMB 851.5m versus RMB 872.7m.

Key financial ratios and metrics

• Q3 basic and diluted EPS were RMB 0.61, up 22.00% YoY; 9M EPS was RMB 1.48, down 1.33%.

• Weighted average ROE was 4.05% for Q3, up 0.70 percentage points; 9M ROE was 9.39%, down 0.47 percentage points.

• At Sept. 30, total assets were RMB 12.337bn and attributable equity was RMB 9.024bn.